Navigation Links
Mirati Therapeutics Reports Third Quarter 2013 Financial Results
Date:11/12/2013

of 2014. We will complete discussions with the FDA to finalize our SPA for the design of a Phase 3 registration trial for mocetinostat in patients with myelodysplastic syndrome. This trial could be started by the second half of 2014."

Third Quarter and Nine Months Ended September 30, 2013 Financial Results Cash, cash equivalents, marketable securities and restricted cash totaled $15.3 million as of September 30, 2013 compared to $37.3 million on December 31, 2012. The cash does not include the $53.0 million in net proceeds from the public offering of 3.25 million shares of the Company's common stock, which closed on October 29, 2013. The Company believes that with the recent financing it has sufficient financial resources to carry forward its current clinical development and operating plans through the end of 2015.

Net research and development expenditures for the third quarter of 2013 were $5.5 million, $1.2 million higher than the third quarter of 2012. The higher expenses primarily reflect increased costs for mocetinostat and MGCD516. Net research and development expenditures were $15.5 million for the first nine months of 2013, compared to $10.1 million for the same period in 2012. Increases were primarily due to the factors listed above as well as increased costs for MGCD265, costs associated with organizational changes implemented in 2013 and a reduction in investment tax credits versus the prior year.

General and administrative expenses in the third quarter of 2013 were $3.7 million, $2.0 million higher than in the third quarter of 2012. General and administrative expenses were $8.6 million in the first nine months, compared to $4.0 million for the same period in 2012. The increase primarily reflects higher share-based compensation costs and costs associated with the recent corporate reorganization and associated management changes.

Other expense, net in the third quarter of 2013 was $20.1 million compared to other income, net of
'/>"/>

SOURCE Mirati Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Mirati Therapeutics Prices Public Offering Of Common Stock
2. Sorrento Therapeutics Adopts Stockholder Rights Plan
3. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
4. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
5. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
6. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
7. Echo Therapeutics Announces Third Quarter 2013 Financial Results
8. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
9. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
10. PDL BioPharma Provides $70 Million in Financing to Durata Therapeutics
11. PTC Therapeutics to Present at Credit Suisse Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  CytoSorbents Corporation (NASDAQ CM: CTSO), a critical ... adsorber to reduce deadly inflammation in critically-ill and ... net of transaction costs, in non-dilutive funding as ... Certificate Transfer Program sponsored by the New Jersey ...
(Date:1/23/2015)... January 23, 2015 Heptares Therapeutics, the clinical-stage ... announce that the Malcolm Campbell Memorial Prize for ... President of Chemistry), Fiona Marshall (Chief Scientific Officer ... and co-founder) for the seminal contributions to GPCR drug discovery ...
(Date:1/22/2015)... 2015  BiOptix is pleased to announce the appointment of ... Chemistry and Biochemistry. Scott joins the company after previous scientific ... throughout the course of his nearly 20 year career ... a nationally recognized thought leader in the biosensor field ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... 2011 Zimmer Holdings, Inc. (NYSE: ZMH ; ... earnings conference call will be broadcast live over the Internet ...  A news release detailing the quarterly results will be made ... conference call. The live audio webcast can ...
... 2011 Lanx ® , Inc., a privately held ... devices for spinal surgery, today announced the launch of ... American Association of Neurological Surgeons (AANS) Annual Meeting, Denver, ... minimally invasive fixation alternative to pedicle screws, intended to ...
Cached Medicine Technology:Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2011 Results 2Lanx®, Inc. Announces Launch of Concero™ Facet Screw System for Spinal Fusion 2
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... , WEDNESDAY, July 13 (HealthDay News) -- People ... but virtual reality- and physical reality-based therapies may provide ... research suggests. In conducting the study, scheduled for ... of Physical Medicine and Rehabilitation , researchers assigned tasks ...
... development assistance from the Georgia Tech Research Institute (GTRI) ... an Atlanta-based company is developing what it hopes will ... hundreds of millions of people who wear glasses or ... To be used by optometrists and ophthalmologists, the ...
... News) -- For patients taking the heart rhythm drug amiodarone ... incidents of thyroid dysfunction than the brand-name medication, researchers report. ... difference between the two drugs, according to the report released ... . Amiodarone, a drug used to control arrhythmia -- ...
... from two major HIV prevention trials announced favorable results of ... of these trials, the Partners PrEP Study, has provided the ... both studies will need to be fully evaluated before it ... major trial that is ongoing. Investigators for VOICE Vaginal ...
... , WEDNESDAY, July 13 (HealthDay News) -- A ... fight the H1N1 epidemic in 2009 may not have boosted ... all. Guillain-Barre is a rare disorder, which causes a ... weakness and even paralysis. In 1976, a vaccine used ...
... (OA) is a leading cause of disability in the ... to raise awareness and increase knowledge of OA among ... American Journal of Nursing and the National Association of ... in the Prevention and Management of Osteoarthritis" on Thursday, ...
Cached Medicine News:Health News:'Virtual Reality' May Help in Parkinson's Therapy 2Health News:R&D collaboration focuses on new system for measuring and improving human vision 2Health News:R&D collaboration focuses on new system for measuring and improving human vision 3Health News:R&D collaboration focuses on new system for measuring and improving human vision 4Health News:Generic, Brand-Name Heart Drugs Seem to Have Same Effect on Thyroid 2Health News:VOICE study will continue as it considers what action to take after results of 2 trials 2Health News:VOICE study will continue as it considers what action to take after results of 2 trials 3Health News:VOICE study will continue as it considers what action to take after results of 2 trials 4Health News:'Swine Flu' Shot May Be Cleared of Guillain-Barre Charges 2Health News:State of the Science in the Prevention and Management of Osteoarthritis-A Conference for Nurses 2
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
... MVR knife. 1.1 mm (19G) with a 1.38 ... Cannula (5/bx, 1 bx/ca). State-of-the-art manufacturing and quality ... precise. Sure grip handles have a ridge indicating ... fluid tight incision for self-sealing wounds. Gauge size ...
For use in cleaning soft contact lenses. Sensitive Eyes daily cleaner loosens and removes accumulations of film, deposits, and debris from soft contact lenses. Use with heat, chemical, and hydrogen p...
Complete Blink-N-Clean lens drops cleans and clears lenses in a blink. It is a unique blend of gentle to the eye ingredients that conveniently cleans, clears and keeps lenses feeling comfortable thro...
Medicine Products: